I graduated from Liverpool University in 1980 with a BSc in Pharmacology and continued in the same department to obtain a PhD on the central control of respiration in 1984. I then moved to the University of Nottingham and commenced an MRC post doctoral research fellowship with Professor CA Marsden and Dr GW Bennett, examining the role of serotonin (5-hydroxytryptamine, 5-HT) in bulbospinal raphe neurones controlling motor function. This established my long-standing interest in the mechanism of action of 5-HT in the CNS and Nottingham has since been my home for this research. In 1988 I was appointed to the position of Lecturer in the Department of Physiology and Pharmacology and I became a Senior lecturer in 1996, a Reader in 2003, and obtained a personal Chair in 2006 in what was then the School of Biomedical Sciences. I was elected a fellow of the British Pharmacological Society in 2012.
My work continues to take a whole animal integrated physiological approach to investigate the functional role of 5-HT and dopamine in the CNS and to evaluate the impact of early-life interventions on brain development and behaviour. A particular interest is trying to develop and validate rodent models that help improve our understanding of the neurobiological basis of common neurodevelopmental disorders. I lead a team of postgraduate research students, post doctoral research fellows and a senior research fellow working on preclinical models of common CNS disorders. I also head the CNS disorders research group of academics within the School of Life Science which has extensive research collaboration with pharmaceutical companies around the world.
I deliver a variety of teaching to the Neuroscience, MPharm and BMedSci degrees at The University of Nottingham. During my time at The University of Nottingham I have served as Admissions tutor,… read more
My research interest is the role of 5-hydroxytryptamine and dopamine in neurological and mental disorders and the impact of lesions, pharmacological or environmental interventions during early-life… read more
KOHLI S, KING MV, WILLIAMS S, EDWARDS A, BALLARD TM, STEWARD LJ, ALBERATI D and FONE KCF, 2019. Oxytocin attenuates phencyclidine hyperactivity and increases social interaction and nucleus accumbens dopamine release in rats. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 44(2), 295-305 DUNPHY DOHERTY F, O’MAHONY SM, PETERSON VL, O’SULLIVAN O, CRISPIE F, COTTER PD, WIGMORE P, KING MV, CRYAN JF and FONE KCF, 2018. Post-Weaning Social Isolation of Rats Leads to Long-term Disruption of the Gut Microbiota-Immune-Brain Axis Brain, Behavior and Immunity. 68, 261-273
WATSON DJ, KING MV, GYERTYÁN I, KISS B, ADHAM N and FONE KC, 2016. The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 26(2), 208-24
I deliver a variety of teaching to the Neuroscience, MPharm and BMedSci degrees at The University of Nottingham. During my time at The University of Nottingham I have served as Admissions tutor, Examination Officer and Senior Tutor for the undergraduate Neuroscience degrees and been a member of the Science Faculty Examination Board for the University. I co-ordinate the MSci Neuroscience undrgraduate placement year. I have been personal supervisor for 35 successful PhD students, External Examiner for over fifty PhD theses in UK, Germany, Italy, Sweden and Australia, and internal examiner for many PhD submissions at The University of Nottingham. I have been the external examiner for the BSc Pharmacology degrees at the University of Liverpool and Belfast University.
My research interest is the role of 5-hydroxytryptamine and dopamine in neurological and mental disorders and the impact of lesions, pharmacological or environmental interventions during early-life on subsequent behavioural and neuronal development. My particular research focus is on the development and assessment of predictive models for schizophrenia, ADHD, depression and anxiety, and cognitive disorders. The fundamental approach is to concomitantly measure neurotransmitter function, neurochemistry and behaviour in paradigms designed to model CNS disorders. Techniques used include behavioural analysis, immunohistochemistry, radiotelemetry, microdialysis, electrophysiology, and MRI to identify changes in neuronal circuits in the brain that underlie the alterations in behaviour and neurophysiology seen. The aim is to gain a better understanding of the neurobiological aetiology of common CNS disorders, such as schizophrenia, depression and ADHD, and to help develop novel therapeutic treatment strategies.
Understanding the neurobiological basis of CNS disorders
Utilising in vivo methodologies to investigate the functional role of orphan receptors in CNS disorders.